Release Summary. Charles River launches nAAVigation Vector Platform, with the capability to reduce viral vector gene therapy program timelines to GMP by 55%.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the ...

Charles River Laboratories International, Inc. today announced the launch of its nAAVigation™ Vector Platform. nAAVigation TM Vector Platform: Accelerating Your AAV Pathway to GMP and Clinic ...

Leveraging decades of Adeno-Associated Virus (AAV) vector contract development and manufacturing (CDMO) experience and biologics testing expertise, Charles River has established a platform which ...